SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Analysts raised questions about Arexvy's revaccination potential and the timeline for broader adoption. GSK's Q4 2024 earnings call highlighted strong performance in specialty medicines ...

but there’s no question that the Delaware ruling is a setback and the stock fall wiped more than £6 billion off GSK’s valuation. The new 102-page opinion contradicts a December 2022 federal ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

“Any debate or questions around the efficacy of vaccination ... Walmsley reminded the JPM audience that the stakes are huge for GSK, as more than half its business comes from the U.S. She ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. ("GSK" or the "Company") (NYSE: GSK) American Depositary Receipts ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...